Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

CellProtect (ex vivo expanded and activated autologous natural killer cells) - Avaris, XNK Therap

Sarclisa (isatuximab-irfc) - Sanofi

http://clinicaltrials.gov/ct2/show/NCT04558931

Feb 18, 2021